Imfinzi sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer

Imfinzi logo

News released from Astra Zeneca on 17th March of the Phase III CASPIAN trial confirmed a sustained, clinically meaningful overall survival (OS) benefit for patients with extensive-stage small cell lung cancer (ES-SCLC) receiving Imfinzi (durvalumab) in combination with a choice of standard-of-care (SoC) chemotherapies treated in the 1st-line setting. 

Imfinzi plus SoC (etoposide and either carboplatin or cisplatin chemotherapy) has already met one primary endpoint in June 2019 by demonstrating a statistically significant and clinically meaningful improvement in OS versus SoC alone.

Imfinzi (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80.

A second arm testing tremelimumab, an anti-CTLA-4 monoclonal antibody, added to Imfinzi and SoC did not meet its primary endpoint of demonstrating a statistically significant improvement in OS.

As part of a broad development programme, Imfinzi is also being tested following concurrent chemoradiation therapy in patients with limited-stage SCLC in the Phase III ADRIATIC trial with data anticipated in 2021.

Keywords: Astra Zeneca, Imfinzi, durvalumab, PD-L1, PD-1, CD80, tremelimumab, CTLA-4

Leave a Reply

Your email address will not be published. Required fields are marked *